Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment

References

• Mayer KH, Venkatesh KK. Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health. 2010;100(10):1867–1876. PubMed PMID: 20724682
   PubMed Web of Science ®Google Scholar
• FDA. Antiretroviral drugs used in the treatment of HIV infection 2018 [ cited 2018 Nov 20]. Available from: https://www.fda.gov/forpatients/illness/hivaids/treatment/ucm118915.htm
   Google Scholar
• DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [cited 2019 Feb 01]. Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
   Google Scholar
• Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):583–598. PubMed PMID: 17696808.
   PubMed Web of Science ®Google Scholar
• Stolbach A, Paziana K, Heverling H, et al. A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol. 2015;11(3):326–341. . PubMed PMID: 26036354
   PubMed Web of Science ®Google Scholar
• Bictegravir (R) [Package insert] Gilead Sciences. Research Foster City, Ca. 2018.
   Google Scholar
• Elvitegravir (R) [Package insert] Gilead Sciences. Research Foster City, Ca. 2014.
   Google Scholar
• Cobicistat (R) [Package insert] Bristol-Myers Squibb. Research Princeton, NJ. 2018.
   Google Scholar
• Ritonavir (R) [Package insert] AbbVie Inc.. Research North Chicago, IL. 2017.
   Google Scholar
• Atazanavir (R) [Package insert] Bristol-Myers Squibb. Research Princeton, NJ. 2018.
   Google Scholar
• Darunavir (R) [Package insert] Janssen Ortho LLC. Research Guarbo, PR. 2015.
   Google Scholar
• Fosamprenavir (R) [Package insert] GlaxoSmithKline. Research Triangle Park, NC. 2009.
   Google Scholar
• Saquinavir (R) [Package insert] Genentech USA. Research South San Francisco, CA. 2016.
   Google Scholar
• Tipranavir (R) [Package insert] Boehringer Ingelheim Pharmaceuticals. Research Ridgefield, CT. 2011.
   Google Scholar
• Delavirdine (R) [Package insert] ViiV Healthcare. Research Triangle Park, NC. 2018.
   Google Scholar
• Doravirine (R) [Package insert] Merck & Co., Inc. Research Whitehouse Station, NJ. 2018.
   Google Scholar
• Efavirenz (R) [Package insert] Bristol-Myers Squibb. Research Princeton, NJ. 2016.
   Google Scholar
• Etravirine (R) [Package insert] Janssen Cilag S.p.A, Research Latina, IT. 2008.
   Google Scholar
• Nevirapine (R) [Package insert] Boehringer Ingelheim Pharmaceuticals. Research Ridgefeild, CT. 2005.
   Google Scholar
• Rilpivirine (R) [Package insert] Janssen Cilag S.p.A. Research Latina, IT. 2011.
   Google Scholar
• Maraviroc (R) [Package insert] Pfizer. Research NY,NY.
   Google Scholar
• Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170(2):229–238. PubMed PMID: 14734438
   PubMed Web of Science ®Google Scholar
• Adherence to HIV antiretroviral therapy HIV insite knowledge base chapter 2005. [cited 2019 Feb 01]. Available from: http://hivinsite.ucsf.edu/insite?page=kb-03-02-09.
   Google Scholar
• Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53(1):557–593.
   PubMedGoogle Scholar
• Obitte NC, Rohan LC, Adeyeye CM, et al. The utility of self-emulsifying oil formulation to improve the poor solubility of the anti HIV drug CSIC [journal article]. AIDS Res Ther. 2013 May 31;10(1):14.
   PubMedGoogle Scholar
• Fukushima K, Terasaka S, Haraya K, et al. Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system. Biol Pharm Bull. 2007;30(4):733–738.
   PubMed Web of Science ®Google Scholar
• Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. 2007/09/01 Clin Pharmacokinet. 2007;469:739–756.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017 Sep 23;390(10101):1499–1510. PubMed PMID: 28750935.
   PubMed Web of Science ®Google Scholar
• Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems [journal article]. J Occup Med Toxicol. 2007;2(1):16.
   PubMedGoogle Scholar
• Roy U, Rodriguez J, Barber P, et al. The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine (Lond). 2015;10(24):3597–3609. PubMed PMID: 26400459; PubMed Central PMCID: PMCPMC4910962
   PubMed Web of Science ®Google Scholar
• Edagwa BJ, Zhou T, McMillan JM, et al. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem. 2014;21(36):4186–4198. PubMed PMID: 25174930; PubMed Central PMCID: PMCPMC4281174
   PubMed Web of Science ®Google Scholar
• Mudra DR, Desino KE, Desai PV. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp. Curr Drug Metab. 2011 Oct;12(8):750–773. PubMed PMID: 21568936
   PubMed Web of Science ®Google Scholar
• Hossain MA, Tran T, Chen T, et al. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. J Pharm Pharmacol. 2017 2017/12/01;69(12):1786–1793.
   PubMed Web of Science ®Google Scholar
• Eron J Jr., Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006 Aug 5;368(9534):476–482. PubMed PMID: 16890834; eng.
   PubMed Web of Science ®Google Scholar
• Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet. 2007;46(9):739–756. . PubMed PMID: 17713972
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011 Apr;50(4):229–244. PubMed PMID: 21348537.
   PubMed Web of Science ®Google Scholar
• Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy. 2009 Nov;29(11):1386–1391. PubMed PMID: 19857154; eng.
   PubMed Web of Science ®Google Scholar
• Jover F, Cuadrado J-M, Andreu L, et al. Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol. 2002;25(5):251–253.
   PubMed Web of Science ®Google Scholar
• Midde NM, Kumar S. Development of NanoART for HIV treatment: minding the cytochrome P450 (CYP) enzymes. J Pers Nanomed. 2015;1(1):24.
   PubMedGoogle Scholar
• Cato A III, Cavanaugh J, Shi H, et al. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998;63(4):414–421.
   PubMed Web of Science ®Google Scholar
• Gong Y, Haque S, Chowdhury P, et al. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. Expert Opin Drug Metab Toxicol. 2019 2019/05/04;15(5):417–427.
   PubMed Web of Science ®Google Scholar
• Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26(3):341–346.
   Google Scholar
• Boffito M, Else L, Back D, et al. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther. 2008;13(7):901–907.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43(1):1–5.
   PubMed Web of Science ®Google Scholar
• Roy U, Rodríguez J, Barber P, et al. The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine (Lond). 2015;10(24):3597–3609. PubMed PMID: 26400459.
   PubMed Web of Science ®Google Scholar
• Rizvi SAA, Saleh AM Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018 2018/01/01/;26(1):64–70. .
   PubMed Web of Science ®Google Scholar
• Parboosing R, Maguire GEM, Govender P, et al. Nanotechnology and the treatment of HIV infection. Viruses. 2012;4(4):488–520. . PubMed PMID: 22590683
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Collier AC, Kharasch ED, et al. Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos. 12/03/received 03/09/accepted. 2011;39(6):1070–1078. PubMed PMID: PMC3100903.
   PubMed Web of Science ®Google Scholar
• Shah L, Amiji MM. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites AU - Vyas, Tushar K. 2006/09/01 Expert Opin Drug Deliv. 2006;35:613–628.
   PubMedGoogle Scholar
• Nair M, Jayant RD, Kaushik A, et al. Getting into the brain: potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev. 2016:103:202–217. PubMed PMID: 26944096.
   PubMed Web of Science ®Google Scholar
• Nowacek AS, Balkundi S, McMillan J, et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release. 2011;150(2):204–211. . PubMed PMID: 21108978
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Osswald HL, Prato G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J Med Chem. 2016;59(11):5172–5208. . PubMed PMID: 26799988
   PubMed Web of Science ®Google Scholar
• Reyataz (R) [Package insert] Bristol-Myers Squibb Company. Princeton, NJ. 2018.
   Google Scholar
• Chattopadhyay N, Zastre J, Wong H-L, et al. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res. 2008;25(10):2262–2271.
   PubMed Web of Science ®Google Scholar
• Singh G, Pai RS, Atazanavir-loaded Eudragit RL. 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal. Drug Deliv. 2016;23(2):532–539.
   PubMed Web of Science ®Google Scholar
• Dash PK, Gendelman HE, Roy U, et al. Long-acting NanoART elicits potent antiretroviral and neuroprotective responses in HIV-1 infected humanized mice. AIDS. 2012;26(17):2135.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Darunavir: a review of its use in the management of HIV-1 infection. Drugs. 2014;74(1):99–125.
   PubMed Web of Science ®Google Scholar
• Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. Aids. 2007;21(6):F11–F18.
   PubMed Web of Science ®Google Scholar
• Bhalekar M, Upadhaya P, Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir. Appl Nanosci. 2017;7(1–2):47–57.
   Web of Science ®Google Scholar
• Desai J, Thakkar H. Effect of particle size on oral bioavailability of darunavir-loaded solid lipid nanoparticles. J Microencapsul. 2016;33(7):669–678.
   PubMed Web of Science ®Google Scholar
• Desai J, Thakkar H. Darunavir-loaded lipid nanoparticles for targeting to HIV reservoirs. AAPS PharmSciTech. 2018;19(2):648–660.
   PubMed Web of Science ®Google Scholar
• Desai J, Thakkar H. Enhanced oral bioavailability and brain uptake of Darunavir using lipid nanoemulsion formulation. Colloids Surf B Biointerfaces. 2019;175:143–149.
   PubMed Web of Science ®Google Scholar
• Augustine R, Ashkenazi DL, Arzi RS, et al. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination. Acta Biomater. 2018;74:344–359.
   PubMed Web of Science ®Google Scholar
• Lopinavir (R) [Package insert] AbbVie Inc.. Research North Chicago, IL. 2016.
   Google Scholar
• Shafran S, Mashinter L, Roberts S. The effect of low‐dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005;6(6):421–425.
   PubMed Web of Science ®Google Scholar
• Negi JS, Chattopadhyay P, Sharma AK, et al. Development and evaluation of glyceryl behenate based solid lipid nanoparticles (SLNs) using hot self-nanoemulsification (SNE) technique. Arch Pharm Res. 2014;37(3):361–370.
   PubMed Web of Science ®Google Scholar
• Negi JS, Chattopadhyay P, Sharma AK, et al. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur J Pharm Sci. 2013;48(1–2):231–239.
   PubMed Web of Science ®Google Scholar
• Ravi PR, Vats R, Dalal V, et al. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation. J Pharm Pharmacol. 2014;66(7):912–926.
   PubMed Web of Science ®Google Scholar
• Ravi PR, Vats R, Dalal V, et al. Design, optimization and evaluation of poly-ɛ-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir. Drug Dev Ind Pharm. 2015;41(1):131–140.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shah L, Amiji MM. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv. 2006;3(5):613–628.
   PubMedGoogle Scholar
• Destache CJ, Belgum T, Goede M, et al. Antiretroviral release from poly (DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother. 2010;65(10):2183–2187.
   PubMed Web of Science ®Google Scholar
• Joshi G, Kumar A, Sawant K. Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles. Drug Deliv. 2016;23(9):3492–3504.
   PubMed Web of Science ®Google Scholar
• Destache CJ, Belgum T, Christensen K, et al. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9(1):198.
   PubMedGoogle Scholar
• Ravi PR, Vats R, Balija J, et al. Modified pullulan nanoparticles for oral delivery of lopinavir: formulation and pharmacokinetic evaluation. Carbohydr Polym. 2014;110:320–328.
   PubMed Web of Science ®Google Scholar
• Garg B, Katare O, Beg S, et al. Systematic development of solid self-nanoemulsifying oily formulations (S-SNEOFs) for enhancing the oral bioavailability and intestinal lymphatic uptake of lopinavir. Colloids Surf B Biointerfaces. 2016;141:611–622.
   PubMed Web of Science ®Google Scholar
• Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990;248(4953):358–361.
   PubMed Web of Science ®Google Scholar
• Shah LK, Amiji MM. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res. 2006;23(11):2638–2645.
   PubMed Web of Science ®Google Scholar
• Boudad H, Legrand P, Lebas G, et al. Combined hydroxypropyl-β-cyclodextrin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm. 2001;218(1–2):113–124.
   PubMedGoogle Scholar
• He Y, Xia D-N, Li Q-X, et al. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation. Acta Pharmacol Sin. 2015;36(9):1151.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shahiwala A, Amiji MM. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm. 2008;347(1):93–101.
   PubMedGoogle Scholar
• Dodiya SS, Chavhan SS, Sawant KK, et al. Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. J Microencapsul. 2011;28(6):515–527.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MÁ, Gascón AR, et al. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166(2):115–123.
   PubMed Web of Science ®Google Scholar
• Kuo Y-C, Su F-L. Transport of stavudine, delavirdine, and saquinavir across the blood–brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. 2007/08/01/ Int J Pharm. 2007;3401:143–152.
   PubMedGoogle Scholar
• Kuo Y-C, Kuo C-Y. Electromagnetic interference in the permeability of saquinavir across the blood–brain barrier using nanoparticulate carriers. Int J Pharm. 2008;351(1–2):271–281.
   PubMed Web of Science ®Google Scholar
• Kuo Y-C, Lee C-L. Methylmethacrylate–sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood–brain barrier. Colloids Surf B Biointerfaces. 2012 2012/02/01/;90:75–82.
   PubMed Web of Science ®Google Scholar
• Venkatesh DN, Baskaran M, Karri VVSR, et al. Fabrication and in vivo evaluation of Nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect. Saudi Pharm Journal. 2015;23(6):667–674.
   PubMed Web of Science ®Google Scholar
• López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis [journal article]. Clin Pharmacokinet. 2002 August 01;41(9):681–690. .
   PubMed Web of Science ®Google Scholar
• Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) Is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287–300.
   PubMed Web of Science ®Google Scholar
• Chaowanachan T, Krogstad E, Ball C, et al. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PloS One. 2013;8(4):e61416–e61416. PubMed PMID: 23630586.
   PubMed Web of Science ®Google Scholar
• Date AA, Shibata A, McMullen E, et al. Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection. J Biomed Nanotechnol. 2015;11(3):416–427. PubMed PMID: 26307825
   PubMed Web of Science ®Google Scholar
• Neurath AR, Strick N, Li -Y-Y, et al. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120 [journal article]. BMC Infect Dis. 2001 September 25;1(1):17.
   PubMedGoogle Scholar
• Intelence (R) [Package insert] Janssen Products. Titusville NJ. 2008.
   Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 2007/07/07/;370(9581):39–48.
   PubMed Web of Science ®Google Scholar
• Group TT-CW. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS. 2007;21(6):F1–F10. PubMed PMID: 00002030-200703300-00001.
   PubMed Web of Science ®Google Scholar
• Yanakakis LJ, Bumpus NN. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012;40(4):803–814. PubMed PMID: 22269145.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Cao S, Bright DK, et al. Nanoparticle-based ARV drug combinations for synergistic inhibition of cell-free and cell–cell HIV transmission. Mol Pharm. 2015;12(12):4363–4374. 2015/12/07.
   PubMedGoogle Scholar
• Viramune (R) [Package insert] Boehringer Ingelheim. Ridgefield, CT. 2018.
   Google Scholar
• Wen B, Chen Y, Fitch WL. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos. 2009;37:1557–1562.
   PubMed Web of Science ®Google Scholar
• Raju A, Reddy AJ, Satheesh J, et al. Preparation and characterisation of nevirapine oral nanosuspensions. Indian J Pharm Sci. 2014 Jan-Feb;76(1):62–71. PubMed PMID: 24799740.
   PubMed Web of Science ®Google Scholar
• Kuo Y-C, Lin P-I, Wang -C-C. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Nanomedicine. 2011 2011/08/01 ;66:1011–1026.
   PubMed Web of Science ®Google Scholar
• Shegokar R, Singh KK. Surface modified nevirapine nanosuspensions for viral reservoir targeting: in vitro and in vivo evaluation. 2011/12/15/ Int J Pharm. 2011;4212:341–352.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Gerber JG, Kerr BM. Delavirdine. 2001/03/01 Clin Pharmacokinet. 2001;403:207–226.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Granda BW, et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001;41(1):85–91. 2001/01/01.
   PubMed Web of Science ®Google Scholar
• Wainberg MA Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir. HIV/AIDS (Auckland, NZ). 2013;5:41–49. PubMed PMID: 23413112.
   PubMedGoogle Scholar
• Preininger L, James C, Sweet M. Rilpivirine: A second-generation nonnucleoside reverse transcriptase inhibitor. Am J Health Syst Pharm. 2012;69(10):857–861.
   PubMed Web of Science ®Google Scholar
• Kovarova M, Council OD, Date AA, et al. Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission. PLoS Pathog. 2015;11(8):e1005075–e1005075. PubMed PMID: 26271040; eng
   PubMed Web of Science ®Google Scholar
• van ‘t Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. 2010;54(5):2042–2050. PubMed PMID: 20160045.
   PubMed Web of Science ®Google Scholar
• Hajimahdi Z, Zarghi A. Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity. Iran J Pharm Res. 2016 Autumn;15(4):595–628. PubMed PMID: 28243261.
   PubMed Web of Science ®Google Scholar
• Dolutegravir (R) [Package insert] GlaxoSmithKline, Research Triangle Park, NC; 2013.
   Google Scholar
• Castellino S, Moss L, Wagner D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57(8):3536–3546. PubMed PMID: 23669385.
   PubMed Web of Science ®Google Scholar
• Podany AT, Scarsi KK, Fletcher CV. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors. 2017/01/01 Clin Pharmacokinet. 2017;561:25–40.
   PubMed Web of Science ®Google Scholar
• Sillman B, Bade AN, Dash PK, et al. Creation of a long-acting nanoformulated dolutegravir. Nat Commun. 2018;9(1):443. 2018/02/06.
   PubMedGoogle Scholar
• McMillan J, Szlachetka A, Slack L, et al. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother. 2017;62(1):e01316–17. PubMed PMID: 29061742.
   PubMed Web of Science ®Google Scholar
• Mandal S, Khandalavala K, Pham R, et al. Cellulose Acetate Phthalate and Antiretroviral Nanoparticle Fabrications for HIV Pre-Exposure Prophylaxis. Polymers. 2017;9(9). doi:10.3390/polym9090423
   PubMed Web of Science ®Google Scholar
• Genvoya (R) [Package insert] Gilead Sciences, Inc., Foster City, CA, 2015.
   Google Scholar
• Gong Y, Chowdhury P, Midde NM, et al. Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages. Biochem Biophys Rep. 2017;12:214–219.
   PubMedGoogle Scholar
• Mohideen M, Quijano E, Song E, et al. Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir. Biomaterials. 2017 2017/11/01/;144:144–154.
   PubMed Web of Science ®Google Scholar
• Mandal S, Prathipati PK, Kang G, et al. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. AIDS. 2017;31(4):469–476. . PubMed PMID: 28121666.
   PubMed Web of Science ®Google Scholar
• Prathipati PK, Mandal S, Pon G, et al. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model [journal article]. Pharm Res. 2017 December 01;34(12):2749–2755.
   PubMed Web of Science ®Google Scholar
• Abel S, Russell D, Whitlock LA, et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol. 2008;65(Suppl 1(Suppl1)):60–67. PubMed PMID: 18333867.
   PubMedGoogle Scholar
• Savage AC, Tatham LM, Siccardi M, et al. Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. Eur J Pharm Biopharm. 2018. 2018/05/17/. doi:10.1016/j.ejpb.2018.05.015.
   Web of Science ®Google Scholar
• Caster JM, Patel AN, Zhang T, et al. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jan;9(1). doi:10.1002/wnan.1416. PubMed PMID: 27312983.
   PubMed Web of Science ®Google Scholar
• Ventola CL. Progress in Nanomedicine: approved and Investigational Nanodrugs. P T. 2017 Dec;42(12):742–755. PubMed PMID: 29234213; PubMed Central PMCID: PMCPMC5720487.
   PubMedGoogle Scholar
• Olivia S, Heather V, Sophie L-D, et al. Preclinical Evaluation of TMC-278 LA, a Long-acting Formulation of Rilpivirine, Demonstrates Significant Protection from Vaginal HIV Infection. AIDS Res Hum Retroviruses. 2014;30(S1):A11–A12.
   Google Scholar
• ClinicalTrials Database: NCT02165202. ClinicalTrials.gov.
   Google Scholar
• ClinicalTrials Database: NCT02547870. ClinicalTrials.gov.
   Google Scholar
• ClinicalTrials Database: NCT02076178. ClinicalTrials.gov.
   Google Scholar
• Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):487–492. PubMed PMID: 25473882.
   PubMed Web of Science ®Google Scholar
• Organization WH. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations–2016 update. World Health Organization; 2016.
   Google Scholar
• Pace M, Frater J. A cure for HIV: is it in sight? 2014/07/01 Expert Rev Anti Infect Ther. 2014;127:783–791.
   PubMed Web of Science ®Google Scholar
• Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41(7):2545–2561. . PubMed PMID: 22334259
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Joshi N, Tao W, et al. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410. 2018/04/12.
   PubMed Web of Science ®Google Scholar
• Johnston MC, Scott CJ. Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy. Drug Discov Today. 2018;30:63–69. 2018/12/01/.
   Google Scholar
• Warren JA, Clutton G, Goonetilleke N. Harnessing CD8(+) T Cells Under HIV Antiretroviral Therapy. Front Immunol. 2019;10:291. doi:10.3389/fimmu.2019.00291. PubMed PMID: 30863403; eng
   PubMed Web of Science ®Google Scholar
• Sacha JB, Ndhlovu LC. Strategies to target non-T-cell HIV reservoirs. Curr Opin HIV AIDS. 2016;11(4):376–382. PubMed PMID: 27023285; eng
   PubMed Web of Science ®Google Scholar
• Williams J, Sayles HR, Meza JL, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond). 2013;8(11):1807–1813. PubMed PMID: 23611617
   PubMed Web of Science ®Google Scholar
• Molino NM, Wang S-W. Caged protein nanoparticles for drug delivery. Curr Opin Biotechnol. 2014 2014/08/01/;28:75–82.
   PubMed Web of Science ®Google Scholar